Steven Stein

5.9k total citations · 2 hit papers
21 papers, 3.7k citations indexed

About

Steven Stein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Steven Stein has authored 21 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Steven Stein's work include Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (9 papers) and Colorectal Cancer Treatments and Studies (4 papers). Steven Stein is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (9 papers) and Colorectal Cancer Treatments and Studies (4 papers). Steven Stein collaborates with scholars based in United States, United Kingdom and Netherlands. Steven Stein's co-authors include Cristina Oliva, David Cameron, Charles E. Geyer, Mario Campone, Agnieszka Jagiełło-Gruszfeld, John Crown, Stephen Chan, Stephen D. Rubin, Bella Kaufman and Arlene Chan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Steven Stein

20 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

2006 2.5k citations Charles E. Geyer, Deborah Lindquist et al. New England Journal of Medicine profile →
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2009 766 citations Stephen Johnston, John Pippen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Stein United States	11	3.0k	1.2k	1.0k	859	762	21	3.7k
Stephen D. Rubin United States	13	2.6k 0.9×	1.3k 1.1×	811 0.8×	1.1k 1.3×	673 0.9×	17	4.0k
Zefei Jiang China	30	2.5k 0.8×	1.2k 1.0×	744 0.7×	1.1k 1.3×	915 1.2×	198	3.8k
Deborah Lindquist United States	10	2.5k 0.8×	938 0.8×	812 0.8×	655 0.8×	648 0.9×	22	3.0k
Alexey Manikhas Russia	23	3.1k 1.0×	1.4k 1.1×	763 0.8×	880 1.0×	1.4k 1.8×	89	3.9k
Ellie Guardino United States	17	3.9k 1.3×	1.3k 1.1×	2.2k 2.2×	860 1.0×	619 0.8×	30	4.7k
Michael W. Lu United States	14	2.9k 0.9×	1.0k 0.8×	1.6k 1.6×	675 0.8×	530 0.7×	18	3.7k
Agnieszka Jagiełło-Gruszfeld Poland	13	3.4k 1.1×	2.4k 2.0×	881 0.9×	1.9k 2.2×	1.3k 1.7×	60	5.4k
Antoinette R. Tan United States	36	4.0k 1.3×	1.5k 1.3×	581 0.6×	1.8k 2.1×	999 1.3×	140	5.4k
José Luiz Pedrini Brazil	16	4.2k 1.4×	1.5k 1.2×	1.6k 1.5×	699 0.8×	1.8k 2.4×	28	5.0k
Florence Dalenc France	33	2.6k 0.9×	1.6k 1.3×	428 0.4×	1.3k 1.5×	1.3k 1.7×	209	4.5k

Countries citing papers authored by Steven Stein

Since Specialization

Citations

This map shows the geographic impact of Steven Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Stein more than expected).

Fields of papers citing papers by Steven Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Stein. The network helps show where Steven Stein may publish in the future.

Co-authorship network of co-authors of Steven Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Stein. A scholar is included among the top collaborators of Steven Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Stein. Steven Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stein, Steven, et al.. (2023). An Object Detection System for Identifying Pollen Species. Journal of Allergy and Clinical Immunology. 151(2). AB83–AB83.

Stein, Steven, et al.. (2020). Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease. Gastroenterology Nursing. 43(4). E159–E171. 1 indexed citations

Slosberg, Eric D., Barinder Kang, Julio A. Peguero, et al.. (2018). Signature program: a platform of basket trials. Oncotarget. 9(30). 21383–21395. 32 indexed citations

Kim, Edward S., David Bernstein, Susan G. Hilsenbeck, et al.. (2015). Modernizing Eligibility Criteria for Molecularly Driven Trials. Journal of Clinical Oncology. 33(25). 2815–2820. 64 indexed citations

Giles, Frank, Sarina A. Piha‐Paul, Alexander I. Spira, et al.. (2014). The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients. Blood. 124(21). 4818–4818. 1 indexed citations

Esteva, Francisco J., Sandra Franco, Abenaa M. Brewster, et al.. (2013). An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer. The Oncologist. 18(6). 661–666. 15 indexed citations

Zhou, Xiaolei, David Cella, David Cameron, et al.. (2009). Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment. 117(3). 577–589. 48 indexed citations

Johnston, Stephen, John Pippen, Xavier Pivot, et al.. (2009). Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 27(33). 5538–5546. 766 indexed citations breakdown →

Maltzman, J., M. Pegram, Saeed Sadeghi, et al.. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.. 1 indexed citations

10.

Press, Michael F., Richard S. Finn, David Cameron, et al.. (2008). HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clinical Cancer Research. 14(23). 7861–7870. 134 indexed citations

11.

Cameron, David & Steven Stein. (2008). Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer. Nature Clinical Practice Oncology. 5(9). 512–520. 60 indexed citations

12.

Kaufman, Bella, et al.. (2008). Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer. SHILAP Revista de lepidopterología. 2 indexed citations

13.

Stein, Steven. (2008). Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer. Biologics. 2(1). 61–61. 8 indexed citations

14.

Geyer, Charles E., Deborah Lindquist, Stephen Chan, et al.. (2006). Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 355(26). 2733–2743. 2498 indexed citations breakdown →

15.

Stein, Steven, et al.. (2004). Gemcitabine and Trastuzumab Combinations for Patients with Metastatic Breast Cancer Overexpressing HER2/neu. Clinical Breast Cancer. 4. S117–S120. 8 indexed citations

16.

Stein, Steven, et al.. (2002). High-Dose Chemotherapy and Stem Cell Support for Breast Cancer. Drugs & Aging. 19(7). 475–485. 4 indexed citations

17.

Stein, Steven, Thomas Peacock, Christopher P. Holroyde, et al.. (2001). Phase II Trial of Toremifene in Androgen-Independent Prostate Cancer. American Journal of Clinical Oncology. 24(3). 283–285. 21 indexed citations

18.

Stein, Steven, Paulo Schiavom Duarte, Abass Alavi, Hongming Zhuang, & Jane Β. Alavi. (2000). Multiple Intraabdominal Soft-Tissue Masses in a Man Awaiting Liver Transplantation. American Journal of Clinical Oncology. 23(5). 506–508. 4 indexed citations

19.

Stein, Steven, et al.. (1997). Gestalt Therapy with the Elderly: On the "Coming of Age" and "Completing Gestalts". Gestalt Review. 1(2). 163–184. 6 indexed citations

20.

Stein, Steven, et al.. (1970). Compensatory Renal Hypertrophy: The Role of Immediate Vascular Changes in its Production. The Journal of Urology. 103(5). 564–568. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact